Correction to: Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline

被引：0
|
作者：
Julia Stockmann
Inge M. W. Verberk
Nina Timmesfeld
Robin Denz
Brian Budde
Julia Lange-Leifhelm
Philip Scheltens
Wiesje M. van der Flier
Andreas Nabers
Charlotte E. Teunissen
Klaus Gerwert
机构：
[1] Ruhr-University Bochum,Competence Center for Biospectroscopy, Center for Protein Diagnostics (PRODI)
[2] Ruhr University Bochum,Department of Biophysics, Faculty of Biology and Biotechnology
[3] Vrije Universiteit Amsterdam,Department of Clinical Chemistry, Neurochemistry Laboratory, Amsterdam Neuroscience
[4] Amsterdam UMC,Department of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience
[5] Vrije Universiteit Amsterdam,Department of Medical Informatics, Biometry and Epidemiology
[6] Amsterdam UMC,undefined
[7] Ruhr University Bochum,undefined
来源：
Alzheimer's Research & Therapy | / 13卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
An amendment to this paper has been published and can be accessed via the original article.
引用
收藏
相关论文
共 50 条
  • [1] Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline
    Julia Stockmann
    Inge M. W. Verberk
    Nina Timmesfeld
    Robin Denz
    Brian Budde
    Julia Lange-Leifhelm
    Philip Scheltens
    Wiesje M. van der Flier
    Andreas Nabers
    Charlotte E. Teunissen
    Klaus Gerwert
    Alzheimer's Research & Therapy, 12
  • [2] Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline
    Stockmann, Julia
    Verberk, Inge M. W.
    Timmesfeld, Nina
    Denz, Robin
    Budde, Brian
    Lange-Leifhelm, Julia
    Scheltens, Philip
    van der Flier, Wiesje M.
    Nabers, Andreas
    Teunissen, Charlotte E.
    Gerwert, Klaus
    ALZHEIMERS RESEARCH & THERAPY, 2020, 12 (01)
  • [3] Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline (vol 12, 169, 2020)
    Stockmann, Julia
    Verberk, Inge M. W.
    Timmesfeld, Nina
    Denz, Robin
    Budde, Brian
    Lange-Leifhelm, Julia
    Scheltens, Philip
    van der Flier, Wiesje M.
    Nabers, Andreas
    Teunissen, Charlotte E.
    Gerwert, Klaus
    ALZHEIMERS RESEARCH & THERAPY, 2021, 13 (01)
  • [4] Plasma Amyloid-β Biomarker Associated with Cognitive Decline in Preclinical Alzheimer's Disease
    Lim, Yen Ying
    Maruff, Paul
    Kaneko, Naoki
    Doecke, James
    Fowler, Christopher
    Villemagne, Victor L.
    Kato, Takashi
    Rowe, Christopher C.
    Arahata, Yutaka
    Iwamoto, Shinichi
    Ito, Kengo
    Tanaka, Koichi
    Yanagisawa, Katsuhiko
    Masters, Colin L.
    Nakamura, Akinori
    JOURNAL OF ALZHEIMERS DISEASE, 2020, 77 (03) : 1057 - 1065
  • [5] Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease
    Chatterjee, Pratishtha
    Elmi, Mitra
    Goozee, Kathryn
    Shah, Tejal
    Sohrabi, Hamid R.
    Dias, Cintia B.
    Pedrini, Steve
    Shen, Kaikai
    Asih, Prita R.
    Dave, Preeti
    Taddei, Kevin
    Vanderstichele, Hugo
    Zetterberg, Henrik
    Blennow, Kaj
    Martins, Ralph N.
    JOURNAL OF ALZHEIMERS DISEASE, 2019, 71 (03) : 775 - 783
  • [6] Amyloid-β Oligomers Relate to Cognitive Decline in Alzheimer's Disease
    Jongbloed, Wesley
    Bruggink, Kim A.
    Kester, Maartje I.
    Visser, Pieter-Jelle
    Scheltens, Philip
    Blankenstein, Marinus A.
    Verbeek, Marcel M.
    Teunissen, Charlotte E.
    Veerhuis, Robert
    JOURNAL OF ALZHEIMERS DISEASE, 2015, 45 (01) : 35 - 43
  • [7] Increases in amyloid-β42 slow cognitive and clinical decline in Alzheimer's disease trials
    Abanto, Jesus
    Dwivedi, Alok K.
    Imbimbo, Bruno P.
    Espay, Alberto J.
    BRAIN, 2024, 147 (10) : 3513 - 3521
  • [8] Cortical pyroglutamate amyloid-β levels and cognitive decline in Alzheimer's disease
    Pivtoraiko, Violetta N.
    Abrahamson, Eric E.
    Leurgans, Sue E.
    DeKosky, Steven T.
    Mufson, Elliott J.
    Ikonomovic, Milos D.
    NEUROBIOLOGY OF AGING, 2015, 36 (01) : 12 - 19
  • [9] Correction to: BMI1 is associated with CSF amyloid-β and rates of cognitive decline in Alzheimer’s disease
    Jun Pyo Kim
    Bo-Hyun Kim
    Paula J. Bice
    Sang Won Seo
    David A. Bennett
    Andrew J. Saykin
    Kwangsik Nho
    Alzheimer's Research & Therapy, 14
  • [10] Plasma amyloid-β oligomers level is a biomarker for Alzheimer's disease diagnosis
    Zhou, L.
    Chan, K. H.
    Chu, L. W.
    Kwan, J. S. C.
    Song, Y. Q.
    Chen, L. H.
    Ho, P. W. L.
    Cheng, O. Y.
    Ho, J. W. M.
    Lam, K. S. L.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2012, 423 (04) : 697 - 702
12345